Zyrtec Drives Profits At UCB
In the first six months of 1996, Belgian chemical and pharmaceutical company UCB achieved an increase of 31% in net profits before exceptional items. Including these items, the first-half net profits advanced from 1.98 billion francs ($65 million) a year ago to 4.24 billion francs. Ordinary profits were 2.9 billion francs, an increase of 30.9% on the previous year.
The firm said that net sales amounted to 26.2 billion francs, down marginally on the like, year-earlier period. UCB divested its packaging activities with retrospective effect from January 1, 1996, it noted.
The pharmaceutical sector continued to expand, said the company. Sales of the antiallergy agent Zyrtec (cetirizine) benefited from two factors: a strong demand in the course of the spring, and the launch of the product in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze